DaVita (NYSE:DVA) Sets New 12-Month High - Here's What Happened

DaVita Inc. (NYSE:DVA - Get Free Report) hit a new 52-week high on Monday . The stock traded as high as $172.17 and last traded at $172.71, with a volume of 12210 shares traded. The stock had previously closed at $170.28.

Wall Street Analyst Weigh In

Several research firms recently commented on DVA. Truist Financial boosted their price target on DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a research note on Monday, October 7th. Barclays boosted their price target on DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, DaVita has an average rating of "Hold" and a consensus price target of $161.80.

DaVita Price Performance

The company has a 50 day simple moving average of $159.50 and a 200-day simple moving average of $154.77. The stock has a market cap of $14.44 billion, a price-to-earnings ratio of 19.00, a PEG ratio of 0.85 and a beta of 0.92. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The firm had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. During the same quarter in the previous year, the company earned $2.85 EPS. The company's quarterly revenue was up 4.6% compared to the same quarter last year. As a group, research analysts anticipate that DaVita Inc. will post 9.71 EPS for the current fiscal year.

Institutional Trading of DaVita

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Transcendent Capital Group LLC bought a new position in DaVita in the 3rd quarter worth approximately $25,000. Blue Trust Inc. grew its holdings in DaVita by 56.4% in the 3rd quarter. Blue Trust Inc. now owns 330 shares of the company's stock worth $54,000 after buying an additional 119 shares in the last quarter. Quarry LP bought a new position in DaVita in the 3rd quarter worth approximately $60,000. Venturi Wealth Management LLC boosted its stake in DaVita by 59.8% during the 4th quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock valued at $61,000 after purchasing an additional 152 shares in the last quarter. Finally, Versant Capital Management Inc boosted its stake in DaVita by 58.7% during the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company's stock valued at $68,000 after purchasing an additional 169 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.